Biogen’s stock rises 4% after releasing new data on late-stage Alzheimer’s drug

Read Full Article At The Original Source

Analysts who parsed through it, said the lack of any new negatives in the report means that they expect the company will take the data to the Food and Drug Administration.


Author: HEDGE

Hedge Accordingly was founded ahead of the global financial crisis in January of 2008, with the goal of providing our readers our unique take on The Latest News on Wall Street, Stocks, #Politics and Business news. Hedge Accordingly produces both original, and aggregated #Wallst news content from top publishers around the world. We curate aggregated content covering the latest news on politics, stocks, wall street, and the tech industry. We also provide free stock charting, quotes and a bitcoin, forex and currency exchange. Learn More About